What is the therapeutic range of Lithium (Eskalith)?
A.
0.6-1.5
B.
0.1-0.5
C.
0.2-0.5
D.
0.4-1.6
The Correct Answer and Explanation is:
The correct answer is A. 0.6-1.5 mEq/L.
Explanation:
Lithium is a mood stabilizer commonly used to treat bipolar disorder and is particularly effective in controlling manic episodes. Understanding its therapeutic range is crucial for effective treatment, as both subtherapeutic levels and toxic levels can pose significant risks.
Therapeutic Range: The therapeutic serum concentration of lithium is typically between 0.6 and 1.5 mEq/L. This range is established to maximize the medication’s efficacy while minimizing the potential for adverse effects.
- Subtherapeutic Levels: When lithium levels fall below 0.6 mEq/L, patients may experience a resurgence of manic or depressive symptoms. Symptoms of inadequate control can include mood instability, irritability, and impulsiveness. Therefore, regular monitoring of serum lithium levels is essential, especially after dosage adjustments or initiation of therapy.
- Toxicity: Levels exceeding 1.5 mEq/L can lead to lithium toxicity, which may present as gastrointestinal disturbances (nausea, vomiting), neurological symptoms (tremors, confusion, ataxia), and renal complications. Severe toxicity, characterized by levels above 2.0 mEq/L, can lead to life-threatening conditions, including seizures and coma.
- Monitoring: Routine monitoring of lithium levels is crucial, particularly during the initial stages of treatment or following any changes in dosage. The frequency of monitoring may depend on the stability of the patient’s lithium levels and any concomitant medications that might affect lithium metabolism.
- Patient Education: It is essential for patients to be educated about the signs of both under-treatment and toxicity. They should be encouraged to maintain consistent hydration, as dehydration can elevate lithium levels due to reduced renal clearance.
In conclusion, maintaining lithium levels within the therapeutic range of 0.6-1.5 mEq/L is vital for optimizing treatment outcomes and minimizing the risk of adverse effects in patients receiving lithium therapy.